Select your country

23.03.2018
STADA: Executive Board of STADA Arzneimittel AG decides to file application related to change of sub-segment of the stock exchange
STADA: Executive Board of STADA Arzneimittel AG decides to file application related to change of sub-segment of the stock exchange

STADA: Executive Board of STADA Arzneimittel AG decides to file application related to change of sub-segment of the stock exchange

Read more

08.03.2018
STADA: Executive Board and Supervisory Board of STADA Arzneimittel AG resolve on a proposal for the appropriation of profits and propose a dividend in the amount of €0.11 per share
STADA: Executive Board and Supervisory Board of STADA Arzneimittel AG resolve on a proposal for the appropriation of profits and propose a dividend in the amount of €0.11 per share

STADA: Executive Board and Supervisory Board of STADA Arzneimittel AG resolve on a proposal for the appropriation of profits and propose a d…

Read more

01.02.2018
STADA Arzneimittel AG: Supervisory Board of STADA Arzneimittel AG appoints Peter Goldschmidt as new Chairman of the Executive Board as of September 1, 2018
STADA Arzneimittel AG: Supervisory Board of STADA Arzneimittel AG appoints Peter Goldschmidt as new Chairman of the Executive Board as of September 1, 2018

The Supervisory Board of STADA Arzneimittel AG appointed Peter Goldschmidt today as new Chairman of the Executive Board as of September 1, 2…

Read more

19.12.2017
STADA: domination and profit and loss transfer agreement pursuant to sections 291 et seqq. AktG concluded between STADA Arzneimittel AG and Nidda Healthcare GmbH
STADA: domination and profit and loss transfer agreement pursuant to sections 291 et seqq. AktG concluded between STADA Arzneimittel AG and Nidda Healthcare GmbH

STADA: domination and profit and loss transfer agreement pursuant to sections 291 et seqq. AktG concluded between STADA Arzneimittel AG and …

Read more

27.09.2017
Supervisory Board of STADA Arzneimittel AG elects Dr. Günter von Au as new Chairman
Supervisory Board of STADA Arzneimittel AG elects Dr. Günter von Au as new Chairman

Supervisory Board of STADA Arzneimittel AG elects Dr. Günter von Au as new Chairman

Read more

25.08.2017
Changes on the Supervisory Board of STADA Arzneimittel AG due to the takeover by Bain Capital and Cinven
Changes on the Supervisory Board of STADA Arzneimittel AG due to the takeover by Bain Capital and Cinven

Changes on the Supervisory Board of STADA Arzneimittel AG due to the takeover by Bain Capital and Cinven

Read more

10.07.2017
Bain Capital and Cinven applied for an exemption from one-year exclusion period for the submission of a renewed voluntary public takeover offer with STADA’s consent
Bain Capital and Cinven applied for an exemption from one-year exclusion period for the submission of a renewed voluntary public takeover offer with STADA’s consent

Bain Capital and Cinven applied for an exemption from one-year exclusion period for the submission of a renewed voluntary public takeover of…

Read more

04.07.2017
Changes in the Executive Board of STADA Arzneimittel AG
Changes in the Executive Board of STADA Arzneimittel AG

Changes in the Executive Board of STADA Arzneimittel AG

Read more

04.07.2017
STADA Arzneimittel AG confirms that Bain Capital and Cinven are considering to apply for an exemption from one-year exclusion period for the submission of a renewed voluntary public takeover offer
STADA Arzneimittel AG confirms that Bain Capital and Cinven are considering to apply for an exemption from one-year exclusion period for the submission of a renewed voluntary public takeover offer

STADA Arzneimittel AG confirms that Bain Capital and Cinven are considering to apply for an exemption from one-year exclusion period for the…

Read more

26.06.2017
STADA Arzneimittel AG: Voluntary public takeover offer by Bain Capital and Cinven not successful
STADA Arzneimittel AG: Voluntary public takeover offer by Bain Capital and Cinven not successful

STADA Arzneimittel AG: Voluntary public takeover offer by Bain Capital and Cinven not successful

Read more

07.06.2017
STADA: Bain Capital and Cinven lower the minimum acceptance threshold for the takeover offer to STADA’s shareholders from 75 percent to 67.5 percent – acceptance period extended until June 22, 2017
STADA: Bain Capital and Cinven lower the minimum acceptance threshold for the takeover offer to STADA’s shareholders from 75 percent to 67.5 percent – acceptance period extended until June 22, 2017

STADA: Bain Capital and Cinven lower the minimum acceptance threshold for the takeover offer to STADA’s shareholders from 75 percent to 67.5…

Read more

10.04.2017
STADA supports the voluntary public tender offer by Bain Capital and Cinven worth Euro 66.00 per share
STADA supports the voluntary public tender offer by Bain Capital and Cinven worth Euro 66.00 per share

STADA supports the voluntary public tender offer by Bain Capital and Cinven worth Euro 66.00 per share

Read more

17.03.2017
STADA raises medium-term growth targets
STADA raises medium-term growth targets

STADA raises medium-term growth targets

Read more

16.02.2017
STADA Arzneimittel AG confirms receipt of another non-binding expression of interest in takeover bid
STADA Arzneimittel AG confirms receipt of another non-binding expression of interest in takeover bid

STADA Arzneimittel AG confirms receipt of another non-binding expression of interest in takeover bid

Read more

12.02.2017
STADA Arzneimittel AG confirms receipt of non-binding expressions of interest in takeover bid
STADA Arzneimittel AG confirms receipt of non-binding expressions of interest in takeover bid

STADA Arzneimittel AG confirms receipt of non-binding expressions of interest in takeover bid

Read more

27.08.2016
STADA: Supervisory Board elects Carl Ferdinand Oetker as new Chairman of the Board
STADA: Supervisory Board elects Carl Ferdinand Oetker as new Chairman of the Board

STADA: Supervisory Board elects Carl Ferdinand Oetker as new Chairman of the Board

Read more

26.08.2016
STADA: Shareholder Meeting resolves to remove supervisory board chairman Dr. Martin Abend from the supervisory board
STADA: Shareholder Meeting resolves to remove supervisory board chairman Dr. Martin Abend from the supervisory board

STADA: Shareholder Meeting resolves to remove supervisory board chairman Dr. Martin Abend from the supervisory board

Read more

22.05.2016
STADA: Significant renewal of Supervisory Board brought forward by two years – Annual General Meeting 2016 postponed to August 26, 2016
STADA: Significant renewal of Supervisory Board brought forward by two years – Annual General Meeting 2016 postponed to August 26, 2016

STADA: Significant renewal of Supervisory Board brought forward by two years – Annual General Meeting 2016 postponed to August 26, 2016

Read more

29.02.2016
STADA: Development as expected in 2015 under difficult framework conditions – dividend to increase – preliminary outlook for 2016 published
STADA: Development as expected in 2015 under difficult framework conditions – dividend to increase – preliminary outlook for 2016 published

STADA: Development as expected in 2015 under difficult framework conditions – dividend to increase – preliminary outlook for 2016 published

Read more

18.12.2015
STADA: Legal action against STADA’s Serbian subsidiary has been resolved
STADA: Legal action against STADA’s Serbian subsidiary has been resolved

STADA: Legal action against STADA’s Serbian subsidiary has been resolved

Read more

24.03.2014
STADA: Successful financial year 2013 – Adjusted EBITDA reaches new record high – Dividend to increase by 32 percent – 2014 outlook adjusted
STADA: Successful financial year 2013 – Adjusted EBITDA reaches new record high – Dividend to increase by 32 percent – 2014 outlook adjusted

STADA: Successful financial year 2013 – Adjusted EBITDA reaches new record high – Dividend to increase by 32 percent – 2014 outlook adjusted…

Read more